Propanc Biopharma Inc (NASDAQ:PPCB) rose 5.4% on Monday after announcing it has applied for a foreign filing license in Spain covering two new provisional patent applications.

The patents — which will be formally filed with IP Australia under Propanc’s wholly owned subsidiary, Propanc Pty Ltd — introduce novel approaches for treating therapy-resistant cancers and fibrosis. The discoveries stem from the company’s ongoing Joint Research and Drug Discovery collaboration with Spanish academic institutions.

One patent focuses on treating cancers that no longer respond to chemotherapy or radiotherapy. The second outlines formulations and methods aimed at addressing fibrosis, including organ-level fibrosis. Notably, this marks Propanc’s first patent describing use of its lead candidate, PRP, for chronic diseases outside oncology.

“The submission of these two patents represents a significant turning point for Propanc and the commercial potential of PRP for treating chronic diseases such as cancer and fibrosis,” said James Nathanielsz, Propanc’s Chief Executive Officer.

Propanc anticipates launching a Phase 1b First-In-Human trial in 2026 to establish the optimal therapeutic dose of PRP, laying the groundwork for subsequent Phase 2 studies evaluating the proenzyme therapy across multiple disease areas.

Propanc Biopharma stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.